MISSOULA, Mont., July 15, 2020 /PRNewswire/ -- Expesicor, a
privately held biopharma company focused on preventing, treating,
and curing neurological disorders, is excited to announce its
collaboration with Massachusetts General Hospital (MGH) in
Boston. Expesicor and MGH are
working to develop a positron emission tomography (PET) imaging
agent to objectively diagnose and measure pain. The project is
supported by a grant from the National Institutes of Health's
Helping to End Addiction Long-term (NIH HEAL) Initiative. MGH
brings world-leading knowledge and expertise from researchers of
varied backgrounds including chemistry, biochemistry, and medical
physics.
"We are excited about this collaboration, particularly its
potential to improve the lives of people living with chronic pain,"
said Dr. Braxton Norwood, CEO of
Expesicor. "This project could revolutionize pain management and
help combat the opioid crisis."
A PET scan is an imaging test that helps reveal how systems in
the body are functioning. PET scans use small amounts of
radioactive drug to visualize activity within organs. This
non-invasive method can sometimes detect disease before other
imaging tests. PET scans are commonly used in the
diagnosis/monitoring of cancer, heart function, Alzheimer's
Disease, and epilepsy.
As a clinical-stage company, Expesicor's pipeline includes
projects ranging from preclinical to Phase II clinical trials. In
addition to PET imaging agents, the company's assets include novel
therapeutics and drug screening tools for neurological disorders
including epilepsy, traumatic brain injury (TBI), chronic traumatic
encephalopathy (CTE), and Alzheimer's Disease.
The research reported in this publication was supported by the
National Institute of Neurological Disorders and Stroke of the
National Institutes of Health under Award Number R43NS115294. The
content is solely the responsibility of the authors and does not
necessarily represent the official views of the National Institutes
of Health.
About Expesicor
Expesicor is a privately held, Montana-based company focused on preventing,
treating, and curing neurological disorders. Expesicor's
development pipeline includes proprietary therapeutics, imaging
probes, and drug screening tools for epilepsy, neurodegenerative
disorders, depression, and other brain disorders. For more
information, visit expesicor.com.
Contact
Expesicor Inc
Box 10205 350 N Meridian Rd
Kalispell MT, 59901 USA
Press@expesicor.com
This release is intended for informational purposes only and
should not be relied upon to make any investment decision, as it
was prepared without regard to any specific objectives, or
financial circumstances. This is not a solicitation to buy or sell
any securities. This release is not intended to provide, and should
not be relied upon for tax, legal, accounting, or investment
advice. The forward-looking statements herein constitute an
expression of opinion, which may or may not prove to be
accurate.
View original
content:http://www.prnewswire.com/news-releases/expesicor-announces-collaboration-with-massachusetts-general-hospital-to-develop-novel-imaging-agents-for-pain-management-301094482.html
SOURCE Expesicor